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Objectives: The Diabetic Peripheral Neuropathic Pain Impact (DPNPI) Measure is a 
patient-reported outcome (PRO) measure developed in accordance with the FDA PRO 
guidance for assessing the impacts of living with Diabetic Peripheral Neuropathic 
Pain (DPNP). A validation study was conducted to evaluate the measurement model 
and properties of the 27-item draft version of the DPNPI. MethOds: A non-inter-
ventional, observational, survey-based validation study enrolled outpatients from 
clinical sites in the United States. Recruitment included diagnosed DPNP patients 
(aged 18-80) both treated and untreated with prescription agents. Subjects com-
pleted a retest survey via mail two weeks after their in-clinic assessment. Analyses 
included assessment of the measurement model (factor analysis), reliability (inter-
nal consistency, test-retest) and validity (content, known-groups) of the DPNPI. IRT 
was utilized to evaluate item fit and function. Results: Out of 124 subjects (56% 
male, mean age 62.8),105 completed the retest survey. Nine items from the draft 
version were deleted due to conceptual issues and/or redundancy. Factor analysis 
confirmed the three hypothesized domains: Physical/Mobility Function; Daily Life; 
Sleep. All domains and the total score were internally consistent (0.91 to 0.96) and 
reproducible (0.84 to 0.91). All a priori convergent validity hypotheses were confirmed 
(p< .001) with moderate-strong association between the total and/or subscale scores 
on the DPNPI measure and other logically related measures (range 0.43 to 0.79). 
Additionally, all a priori hypothesized associations for content and known-group 
validity of domains and total score were confirmed (p< .001) and IRT fit statistics 
were within acceptable range. cOnclusiOns: The final 18-item version of the 
DPNPI can be considered a well-designed, valid and reliable measure of the impact 
of DPNP on patients’ daily lives and physical functioning. This measure can be used 
as an endpoint in clinical trials to assess impacts related to DPNP. Further study is 
needed to understand the responsiveness of the DPNPI.
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Objectives: Hypoglycemia burden is the most common problem in patients with 
type 2 diabetes mellitus (T2DM) receiving insulin treatment. However, how hypogly-
cemia affects quality of life (QoL) and treatment satisfaction in this patient popula-
tion is less clear. We aimed to study the QoL and treatment satisfaction in T2DM 
patients on basal-bolus insulin therapy with the absence and presence of different 
types of hypoglycemia. MethOds: A total of 500 T2DM patients receiving basal-
bolus insulin therapy for at least 6 months were enrolled in the survey: male/female 
122/378; mean (SD) age 61.8 (8.4) yrs; mean (SD) time from T2DM diagnosis 12.8 (6.9) 
yrs. Mean HbA1c level was 8.3%. Patients were classified as with no, non-severe, 
severe and nocturnal hypoglycemia events during the last month. Patients filled 
out SF-36 and Patient Treatment Satisfaction Questionnaire. The impact of hypo-
glycemia on QoL and treatment satisfaction was examined through multivariate 
regression, adjusting for sociodemographics and disease status. QoL and treatment 
satisfaction scores were analyzed using t-test, ANOVA, Chi-square test. Results: 
After adjustment, QoL and treatment satisfaction decreased with the increase of 
hypoglycemia events (p< 0.05). Patients with hypoglycemia had significantly lower 
QoL scores for 6 out of 8 SF-36 scales as compared to those without hypoglyce-
mia (p< 0.05). Treatment satisfaction was higher in patients without hypoglycemia 
than in those with hypoglycemia (mean score 7.25 vs 8.0; p= 0.01). Patients with 
nocturnal and severe hypoglycemia had significant reduction of role-physical, 
social functioning, vitality and pain as compared to patients with non-severe 
hypoglycemia (p< 0.05). The percentage of patients who were completely dissatis-
fied or poorly satisfied with treatment was higher in the group with severe or/and 
nocturnal hypoglycemia than in those with non-severe hypoglycemia (20% vs 8%; 
p= 0.002). cOnclusiOns: Hypoglycemia has negative impact on QoL and treatment 
satisfaction in T2DM patients. Severe and nocturnal hypoglycemia significantly 
decreases QoL and reduces treatment satisfaction.
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Objectives: The QoL-AGHDA assesses quality of life (QoL) specific to adults with 
Growth Hormone Deficiency (GHD). Questionnaire content was derived from quali-
tative interviews conducted with individuals who had the condition. Since its devel-
opment a number of new language adaptations have been made for Europe (9), 
Eastern Europe (4), and Central and South America (2). New language versions of 
the measure were required for use in two major new multinational clinical trials. 
These were for Greece, Hungary, Israel, Romania, Russia, Slovakia, Ukraine and the 
US (Spanish). MethOds: The dual-panel methodology was employed to translate 
each of these measures. This approach has been used in the adaptation of all needs-
based QoL measures. Two panels are held. The first employs local people who are 
also proficient in English who agree the most appropriate translation for the instruc-
tions and items. The second panel involves lay people who ensure that the level of 
language is appropriate and will be understood by future respondents. Following 
translation, cognitive debriefing interviews were conducted with adults with GHD 
in each country. Results: No major difficulties were experienced in producing 
Objectives: Foot ulceration is a major cause of disability in diabetes. The aim 
of this study was to estimate influence of severity of diabetic foot ulceration on 
HRQoL. MethOds: A survey among DFS (Diabetic Foot Syndrome) patients with 
active foot ulceration treated in ambulatory care was conducted. The PEDIS scale 
was used to classify severity of ulceration. To assess the impact of diabetic ulcera-
tion on HRQoL in DFS patients the EQ-5D-3L questionnaire was used. Utility scores 
were calculated based on Polish EQ-5D value set (Golicki et al.) Results: Between 
April 2012 and May 2013 185 patients were questioned directly. 179 of them (131 
males) completed the EQ-5D questionnaire and had full record on ulceration sever-
ity (the PEDIS scale). The mean age of patients was 61.9±10.6 years. Diabetes type 
2 was diagnosed in 150 (83.8%) patients while diabetes type 1 in 26 (14.5%). Other 
type of diabetes was diagnosed in 2 persons and data on one were missing. Mean 
time from the diagnosis of diabetes was 18.0±11.1 years. 99 (55%) and 69 (39%) 
patients had grade 1 and 2 perfusion, respectively. The mean ulceration size was 
6.2±13.4 cm2. 74 (41.3%), 65 (36.3%) and 40 (22.3%) patients had grade 1, 2 and 3 
depth/tissue loss respectively. 84 (46.9%), 55 (30.7%) and 36 (20.1%) patients had 
grade 1, 2 and 3 infection, respectively. Most patients (89.4%) had loss of protective 
sensation (grade 2 sensation). Mean utility value in overall population was esti-
mated at 0.618±0.320. Very week negative correlation was found between ulcera-
tion size and utility value. Despite some differences in utility value in patients 
with different perfusion grade no strict correlations between severity of ulceration 
and utility values were found. cOnclusiOns: There is little or no strict correla-
tion between severity of ulceration measured with the PEDIS scale and HRQoL 
measured with the EQ-5D.
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Objectives: EUprimecare is an European Union project aimed at analyzing the 
costs and quality of the different models of primary care (PC) in Europe. The aim 
of this study is to analyze the management of diabetic patients in PC services in 
Spain compared to other European countries, the satisfaction of these patients 
with PC services and their self-perceived health status. MethOds: We conducted 
a population survey by telephone among PC users in each of the consortium 
countries (Germany, Spain, Estonia, Finland, Hungary, Italy and Lithuania). The 
questionnaire included information on sociodemographic characteristics, health 
status, satisfaction, utilization of PC services, and frequency of some interven-
tions carried out by PC professionals. The survey was conducted to 431-432 PC 
users in each country (Ntotal = 3020). Results: The percentage of diabetic 
patients in Spain was 6.7% (N = 29), lower than the overall average (9.1%). Eighty 
three percent of patients living in Spain were diagnosed by their PC physicians 
compared with 73% of the European average. Eighty six percent of patients in 
Spain said that they were being treated for diabetes (EU average = 84%) and in 
88% of these cases the treatment was prescribed by their PC doctor (EU average 
= 70%). Only 6.9% of patients said their health was poor or very poor, the lowest 
proportion of all countries assessed. The overall satisfaction with PC services 
among diabetic patients was 4.10 points on a scale of 1 to 5. Satisfaction in Spain 
was below the global average for all the items measured. cOnclusiOns: Diabetic 
patients in Spain are more frequently controlled by PC professionals than in 
other European countries. These patients have a better self-perceived health 
status and the results of this study suggest a lower level of dissatisfaction with 
the services provided by PC.
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Objectives: There is limited evidence available regarding patient preferences 
for treatment alternatives, including those treatment characteristics that have 
greatest influence on the perceived value, and how this knowledge can be used 
in health care decision-making. The objective of this study was to identify and 
elicit patient preferences for treatments in Type-II-Diabetes in different patient 
groups. MethOds: In order to elicit patient preferences this study used an 
explorative qualitative approach in combination with quantitative survey tech-
niques. Literature research and semi-structured interviews (N= 15) were the basis 
of quantitative elicitations (N= 388) using Analytic-Hierarchy-Process (AHP) and 
Best-Worst-Scaling (BWS). The study aimed at the determination of the relative 
importance of patient-relevant decision criteria as well as to compare two meth-
ods of measuring preference. In total, seven therapy-related attributes (three lev-
els each) were tested. The sample contained patients receiving oral anti-diabetics 
(OAD) (N= 200) or insulin (N= 188). Results: The qualitative study identified 22 
patient-relevant treatment-characteristics. Out of these the seven most impor-
tant were included in AHP and BWS. The AHP- as well as BWS-surveys resulted in 
a dominance of the attribute “HbA1c-Level”, for both OAD- and Insulin-patients. 
In the OAD-group AHP and BWS independently showed the same ranking of the 
three attributes: “Delay of Insulin-Therapy” (Rank 2), “Occurrence of hypoglyce-
mia” (Rank 3) and “Weight changes” (Rank 4). In the Insulin-group “Occurrence 
of hypoglycemia” was ranked second using AHP and third within BWS. “Weight 
changes” were ranked equally in both methods. However their relevance among 
different patient groups changed. cOnclusiOns: In both patient-groups AHP 
and BWS show similar results. Nonetheless both groups have different horizons 
of experience and differ in the ranking of decision criteria. For the first time the 
methods of AHP and BWS were used to assess patients’ preferences for different 
characteristics of treatment in Type-II-Diabetes, as well as the influence of those 
criteria on the patient benefit.
